Thierry Van Nieuwenhove, CEO, Quotient Sciences discusses how Translational Pharmaceutics® combines drug product formulation with clinical pharmacology, overcoming the typical industry separation between these services to accelerate the development pipeline for both large and small pharma. This integrated model delivers significant time savings, often between nine and twelve months, and provides a faster path to proof of concept (PoC). To meet the industry challenge of continued acceleration, Quotient Sciences is enhancing this capability by integrating AI algorithms to reduce formulation time by 50% and by adding patient cohorts to reach PoC even faster within a single clinical trial. Having successfully applied this methodology across more than 600 products over 18 years, the company is now applying Translational Pharmaceutics to the biologics space.
